• Something wrong with this record ?

Effect of metoprolol in hypertrophic obstructive cardiomyopathy patients after alcohol septal ablation

H. Hnátová, K. Fulínová, B. Řiháková, J. Bonaventura, J. Veselka

. 2023 ; 49 (-) : 101317. [pub] 20231202

Status not-indexed Language English Country Ireland

Document type Journal Article

BACKGROUND: The use of beta-blockers in hypertrophic obstructive cardiomyopathy (HOCM) patients after alcohol septal ablation (ASA) lacks data support. We aimed to evaluate the effect of metoprolol on exercise capacity, hemodynamic and laboratory parameters, and quality of life in HOCM patients after ASA. METHODS: This was a prospective randomized single-center open-label crossover trial in 21 HOCM patients after ASA. Patients received metoprolol and no beta-blocker for two periods of three months. The endpoints were: peak oxygen uptake (pVO2), maximal left ventricular outflow tract (LVOT) pressure gradient at peak exercise, a ratio of mitral peak velocity of the early filling (E) to early diastolic mitral annular velocity (e') (E/e') at rest, Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score, and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) plasmatic concentration. RESULTS: No significant association was found between the treatment and any of the endpoints in the assessed patients: 1) pVO2 (19.5 ± 5.3 ml/kg/min vs. 19.4 ± 4.1 ml/kg/min, p = 0.90), 2) exercise-induced pressure gradient in LVOT 32 ± 37 mmHg vs. 32 ± 30 mmHg, p = 0.84, 3) E/e' ratio at rest (11 ± 4 vs. 10 ± 4, p = 0.23), 4) KCCQ overall summary score (78 ± 11 vs. 77 te ± 15, p = 0.56), 5) NT-proBNP (215 pg/ml [121-333] vs. 153 pg/ml [102-228], p = 0.19). CONCLUSIONS: In HOCM patients after successful ASA, metoprolol treatment did not improve exercise capacity, hemodynamic and laboratory parameters, or quality of life.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23022387
003      
CZ-PrNML
005      
20240116163025.0
007      
ta
008      
240105s2023 ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ijcha.2023.101317 $2 doi
035    __
$a (PubMed)38126007
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Hnátová, Hana $u Department of Cardiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
245    10
$a Effect of metoprolol in hypertrophic obstructive cardiomyopathy patients after alcohol septal ablation / $c H. Hnátová, K. Fulínová, B. Řiháková, J. Bonaventura, J. Veselka
520    9_
$a BACKGROUND: The use of beta-blockers in hypertrophic obstructive cardiomyopathy (HOCM) patients after alcohol septal ablation (ASA) lacks data support. We aimed to evaluate the effect of metoprolol on exercise capacity, hemodynamic and laboratory parameters, and quality of life in HOCM patients after ASA. METHODS: This was a prospective randomized single-center open-label crossover trial in 21 HOCM patients after ASA. Patients received metoprolol and no beta-blocker for two periods of three months. The endpoints were: peak oxygen uptake (pVO2), maximal left ventricular outflow tract (LVOT) pressure gradient at peak exercise, a ratio of mitral peak velocity of the early filling (E) to early diastolic mitral annular velocity (e') (E/e') at rest, Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score, and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) plasmatic concentration. RESULTS: No significant association was found between the treatment and any of the endpoints in the assessed patients: 1) pVO2 (19.5 ± 5.3 ml/kg/min vs. 19.4 ± 4.1 ml/kg/min, p = 0.90), 2) exercise-induced pressure gradient in LVOT 32 ± 37 mmHg vs. 32 ± 30 mmHg, p = 0.84, 3) E/e' ratio at rest (11 ± 4 vs. 10 ± 4, p = 0.23), 4) KCCQ overall summary score (78 ± 11 vs. 77 te ± 15, p = 0.56), 5) NT-proBNP (215 pg/ml [121-333] vs. 153 pg/ml [102-228], p = 0.19). CONCLUSIONS: In HOCM patients after successful ASA, metoprolol treatment did not improve exercise capacity, hemodynamic and laboratory parameters, or quality of life.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Fulínová, Klára $u Department of Cardiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Řiháková, Barbora $u Department of Cardiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Bonaventura, Jiří $u Department of Cardiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Veselka, Josef $u Department of Cardiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
773    0_
$w MED00198717 $t International journal of cardiology. Heart & vasculature $x 2352-9067 $g Roč. 49, č. - (2023), s. 101317
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38126007 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240105 $b ABA008
991    __
$a 20240116163021 $b ABA008
999    __
$a ok $b bmc $g 2036263 $s 1208832
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 49 $c - $d 101317 $e 20231202 $i 2352-9067 $m International journal of cardiology Heart & vasculature $n Int J Cardiol Heart Vasc $x MED00198717
LZP    __
$a Pubmed-20240105

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...